Literature DB >> 21756027

The role of CD40/CD40L and interferon regulatory factor 4 in Hodgkin lymphoma microenvironment.

Donatella Aldinucci1, Annunziata Gloghini, Antonio Pinto, Alfonso Colombatti, Antonino Carbone.   

Abstract

Inflammation and cancer are two independent biological events that can play an interdependent role. The model of such interaction is represented by Hodgkin lymphoma (HL), where the microenvironment is dominated by an extensive mixed, potentially cellular inflammatory infiltrate that plays a decisive role in the pathobiology of HL. In this review we summarize updated information on the complex interactions between Hodgkin Reed-Sternberg (HRS) cells and their tissue microenvironment, highlighting the functional role of CD40/CD40L and interferon regulatory factor 4 (IRF4).

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21756027     DOI： 10.3109/10428194.2011.605190

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


  16 in total

Review 1.  Microenvironment abnormalities and lymphomagenesis: Immunological aspects.

Authors:  Joseph G Taylor; John G Gribben
Journal:  Semin Cancer Biol       Date:  2015-07-29       Impact factor: 15.707

2.  Novel Molecular Mechanism of Regulation of CD40 Ligand by the Transcription Factor GLI2.

Authors:  Weiguo Han; David A Jackson; Stephan J Matissek; Jason A Misurelli; Matthew S Neil; Brandon Sklavanitis; Nansalmaa Amarsaikhan; Sherine F Elsawa
Journal:  J Immunol       Date:  2017-05-01       Impact factor: 5.422

Review 3.  Customized targeted therapy in Hodgkin lymphoma: hype or hope?

Authors:  Catherine Diefenbach; Ranjana Advani
Journal:  Hematol Oncol Clin North Am       Date:  2014-02       Impact factor: 3.722

4.  Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma.

Authors:  Michelle Fanale; Sarit Assouline; John Kuruvilla; Philippe Solal-Céligny; Dae S Heo; Gregor Verhoef; Paolo Corradini; Jeremy S Abramson; Fritz Offner; Andreas Engert; Martin J S Dyer; Daniel Carreon; Brett Ewald; Johan Baeck; Anas Younes; Arnold S Freedman
Journal:  Br J Haematol       Date:  2013-11-13       Impact factor: 6.998

Review 5.  The role of T cells in the microenvironment of Hodgkin lymphoma.

Authors:  Frederik Wein; Ralf Küppers
Journal:  J Leukoc Biol       Date:  2015-08-28       Impact factor: 4.962

Review 6.  Role of immune escape mechanisms in Hodgkin's lymphoma development and progression: a whole new world with therapeutic implications.

Authors:  Luis de la Cruz-Merino; Marylène Lejeune; Esteban Nogales Fernández; Fernando Henao Carrasco; Ana Grueso López; Ana Illescas Vacas; Mariano Provencio Pulla; Cristina Callau; Tomás Álvaro
Journal:  Clin Dev Immunol       Date:  2012-08-15

7.  Serum levels of chemokines CCL4 and CCL5 in cirrhotic patients indicate the presence of hepatocellular carcinoma.

Authors:  M Sadeghi; I Lahdou; H Oweira; V Daniel; P Terness; J Schmidt; K-H Weiss; T Longerich; P Schemmer; G Opelz; A Mehrabi
Journal:  Br J Cancer       Date:  2015-08-13       Impact factor: 7.640

Review 8.  New antibody approaches to lymphoma therapy.

Authors:  Tejas Suresh; Lisa X Lee; Jitesh Joshi; Stefan K Barta
Journal:  J Hematol Oncol       Date:  2014-09-09       Impact factor: 17.388

9.  Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin's lymphoma with an emphasis on targeted therapies and transplantation strategies.

Authors:  Theodoros Karantanos; Ioannis Politikos; Vassiliki A Boussiotis
Journal:  Blood Lymphat Cancer       Date:  2017-05-09

Review 10.  The inflammatory chemokine CCL5 and cancer progression.

Authors:  Donatella Aldinucci; Alfonso Colombatti
Journal:  Mediators Inflamm       Date:  2014-01-02       Impact factor: 4.711
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.